Subtype
Pancreatic Carcinoma
CI-CAN-00003562Explore in graph →
488 active trials5 approved drugs31 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003562Explore in graph →
Clinical trials
1,381 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (201)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05141643 | Imaging Study of 18F-FAC PET Scans to Assess Standard Treatment in People With Pancreatic Cancer | active not recruiting | Early Phase 1 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07644559 | A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer | recruiting | Phase 2 | 180 | Verastem, Inc.INDUSTRY | 3 | Sep 3, 2026 | clinicaltrials |
| NCT05245500 |
| Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion |
| recruiting |
| Phase 1 |
| 336 |
| Bristol-Myers SquibbINDUSTRY |
| 1 |
| Sep 2, 2026 |
| clinicaltrials |
| NCT05247905 | Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors, the ComPareNET Trial | active not recruiting | Phase 2 | 31 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06673017 | PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC) | recruiting | Phase 1 | 26 | PanTher TherapeuticsINDUSTRY | 2 | Sep 2, 2026 | clinicaltrials |
| NCT06995898 | The Vanguard Study: Testing a New Way to Screen for Cancer | recruiting | N/A | 24,000 | National Cancer Institute (NCI)NIH | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07024615 | A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer | recruiting | Phase 1 | 25 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07799298 | Spleen Preservation Versus Splenectomy in Left Pancreatectomy for Pancreatic Ductal Adenocarcinoma (SPLENDID)(SPLENDID RCT) | not yet recruiting | N/A | 360 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT02676349 | Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44) | completed | Phase 2 | 130 | Institut de Cancérologie de LorraineOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT04172532 | Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 92 | National Cancer Institute (NCI)NIH | 1 | Sep 1, 2026 | clinicaltrials |
| NCT05526443 | Austrian Registry for Evaluation of Treatment Patterns and Outcome in Patients With Advanced Pancreatic Ductal Adenocarcinoma (PDAC)(ADPACA) | recruiting | — | 1,500 | Medical University of GrazOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT06305247 | A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours | active not recruiting | Phase 1 / Phase 2 | 36 | IpsenINDUSTRY | 3 | Sep 1, 2026 | clinicaltrials |
| NCT07573215 | Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma | approved for marketing | — | — | Revolution Medicines, Inc.INDUSTRY | 2 | Sep 1, 2026 | clinicaltrials |
| NCT07796594 | Integration of Whole-Genome Sequencing PrOfiles and ImmuNe StATus in Cancer(SONATA) | active not recruiting | N/A | 180 | Amsterdam UMC, location VUmcOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07796997 | GI-06: The Impact of Perioperative Hydrocortisone on Patients Undergoing Partial Pancreatectomy | not yet recruiting | Phase 1 | 20 | University of Illinois at ChicagoOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT05497531 | Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers | recruiting | N/A | 15 | University of California, IrvineOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT06084013 | Use Of Indocyanine Green In Pancreas Surgery | recruiting | — | 55 | OHSU Knight Cancer InstituteOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT06582017 | Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma | recruiting | Phase 1 | 100 | Nammi Therapeutics IncINDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT06698458 | Alpha Radiation Emitters (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer | recruiting | N/A | 50 | Alpha Tau Medical LTD.INDUSTRY | 3 | Aug 27, 2026 | clinicaltrials |
| NCT07227168 | A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer | recruiting | Phase 1 | 200 | Sutro Biopharma, Inc.INDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07630961 | Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors | recruiting | Phase 1 | 66 | Novartis PharmaceuticalsINDUSTRY | 2 | Aug 27, 2026 | clinicaltrials |
| NCT07640295 | Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations | recruiting | Phase 1 / Phase 2 | 80 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT04157127 | Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma(DECIST) | recruiting | Phase 1 | 18 | Diakonos Oncology CorporationINDUSTRY | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07494994 | SURGIMEDIA: Utilization of Multimedia for Enhanced Surgical Consent(SURGIMEDIA) | not yet recruiting | N/A | 60 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07787156 | Reach and Engagement of GENetic Education, Risk Assessment, and TEsting Feasibility Trial(REGENERATE) | not yet recruiting | N/A | 80 | Brigham and Women's HospitalOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT02206360 | Pancreatic Cancer Early Detection Program(PCEDP) | completed | — | 181 | White Plains HospitalOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT04851119 | Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors | recruiting | Phase 1 / Phase 2 | 147 | Children's Oncology GroupNETWORK | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06958328 | Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer(LAP100) | recruiting | Phase 3 | 356 | NRG OncologyOTHER | 2 | Aug 25, 2026 | clinicaltrials |
| NCT07594626 | BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion | recruiting | Phase 1 / Phase 2 | 72 | Northwestern UniversityOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT05517811 | Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection(TEG) | recruiting | — | 200 | University of Colorado, DenverOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT06586515 | MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors(MOONRAY-01) | recruiting | Phase 1 | 630 | Eli Lilly and CompanyINDUSTRY | 9 | Aug 24, 2026 | clinicaltrials |
| NCT04147494 | Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues | active not recruiting | Early Phase 1 | 29 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT05554367 | Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial | active not recruiting | Phase 2 | 199 | National Cancer Institute (NCI)NIH | 2 | Aug 21, 2026 | clinicaltrials |
| NCT06843551 | The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation(EMPIRE) | recruiting | Phase 2 | 20 | Benjamin SpielerOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT04673448 | Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer | active not recruiting | Phase 1 | 18 | University of WashingtonOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04851106 | Evaluation of Endoscopic Ultrasound Shear Wave Elastography (EUS-SWE) for the Diagnosis of Pancreatic Adenocarcinoma.(EDEN) | completed | — | 130 | GCS Ramsay Santé pour l'Enseignement et la RechercheOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04902872 | Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 69 | Cybrexa TherapeuticsINDUSTRY | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07274657 | Superb Microvascular Imaging (SMI) and Two-Dimensional Endoscopic Ultrasound Guided Shear Wave Elastography (2D-SWE-EUS) in Differential Diagnosis of Pancreatic Adenocarcinoma (PA) From Other Pancreatic Solid Lesions (PSLs) and Pancreatic neuroendocrinE Tumors (pNETs) Malignancy(SMILE) | recruiting | N/A | 150 | GCS Ramsay Santé pour l'Enseignement et la RechercheOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07608458 | Scheduled Meditation for Improving Postoperative Outcomes in Patients Undergoing Pancreatectomy | not yet recruiting | N/A | 70 | City of Hope Medical CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07619313 | AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer | recruiting | Phase 1 | 46 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07776353 | Understanding New Cachexia Subtypes Through Observational Epidemiological Research(UNCOVER) | recruiting | — | 800 | Kaiser PermanenteOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07777211 | A Phase I/IIa Study of GKL-006 Injection in Patients With Advanced Pancreatic Cancer | active not recruiting | Phase 1 / Phase 2 | 52 | Beijing Gene Key Life Technology Co., LtdINDUSTRY | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04550494 | Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations | active not recruiting | Phase 2 | 29 | National Cancer Institute (NCI)NIH | 1 | Aug 19, 2026 | clinicaltrials |
| NCT05220046 | Palliadelic Treatment to Reduce Psychological Distress in Persons With Advanced Gastrointestinal Cancers | completed | Phase 1 | 18 | University of NebraskaOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT05692323 | A Supervised Prehabilitation Program for Patients With Pancreatic Cancer(PREHAB) | active not recruiting | N/A | 16 | Cedars-Sinai Medical CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07175389 | JDB153 Combined With Serplulimab for Pancreatic Cancer After Standard Treatment Failure | not yet recruiting | Phase 1 / Phase 2 | 10 | West China HospitalOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07214298 | Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma | recruiting | Phase 1 / Phase 2 | 35 | Roswell Park Cancer InstituteOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07226154 | Prediction of Neoadjuvant Chemotherapy Response in Pancreatic Cancer(PRECEPT) | recruiting | — | 200 | City of Hope Medical CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07542041 | Artidis Nanomechanical Signature Profiling of Pancreatic Cancer Specimens(ANoPs) | recruiting | N/A | 200 | ARTIDIS AGINDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Sep 3, 2026source: clinicaltrials